Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Development of immuno- nanoparticles for targeting schistosoma parasites
Praziquantel (PZQ) is the drug of choice for treatment of schistosomiasis since its discovery in 1972. According to World Health Organization (WHO), schistosomiasis is the second most prevalent parasitic disease worldwide that has no effective vaccine yet. Schistosoma parasites infect more than 200...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis |
| Published: |
AUC Knowledge Fountain
2017
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867613419051417600 |
|---|---|
| access_status_str | Open Access |
| author | Abdul-Ghany, Eman Rabie |
| author_browse | Abdul-Ghany, Eman Rabie |
| author_facet | Abdul-Ghany, Eman Rabie |
| author_sort | Abdul-Ghany, Eman Rabie |
| collection | Thesis |
| dc_rights_str_mv | The author retains all rights with regard to copyright. The author certifies that written permission from the owner(s) of third-party copyrighted matter included in the thesis, dissertation, paper, or record of study has been obtained. The author further certifies that IRB approval has been obtained for this thesis, or that IRB approval is not necessary for this thesis. Insofar as this thesis, dissertation, paper, or record of study is an educational record as defined in the Family Educational Rights and Privacy Act (FERPA) (20 USC 1232g), the author has granted consent to disclosure of it to anyone who requests a copy. |
| description | Praziquantel (PZQ) is the drug of choice for treatment of schistosomiasis since its discovery in 1972. According to World Health Organization (WHO), schistosomiasis is the second most prevalent parasitic disease worldwide that has no effective vaccine yet. Schistosoma parasites infect more than 200 million people in about 76 countries and about 700 million people are at risk.PZQ is not only used for treatment of schistosomiasis, but it is also used for control of other parasitic diseases and it is included on the Model List of Essential Medicines of WHO. Parasitic diseases, despite their significant global burden, have been rather under researched by drug discovery companies as compared to other diseases mainly due to complexities of parasitic infections and lack of economic motivations. In such scenario, nanomedicine has a crucial role to play in improvement of the current anti-parasitic agents by their delivering in a targeted manner to the schistosome parasites in host blood circulation. Hence, selective drug delivery is an important approach with great potential for overcoming problems associated with the systemic toxicity and poor bioavailability of PZQ. This study aims at overcoming the inherent drawbacks of PZQ through formulation, optimization and evaluation of PZQ-loaded biodegradable PLGA “Poly (D,L lactide-coglycolide)” nanoparticles (NPs) that were surface conjugated with polyclonal antibodies (pAb) specific for schistosome surface antigens (sAg) for active targeting and treatment of schistosomiasis. PZQ was encapsulated in biodegradable PLGA NPs using single emulsion-solvent evaporation method. Various parameters were investigated and optimized like drug: polymer ratio, surfactant concentration and osmotic effect of adding salts to the external aqueous phase. PZQ-loaded NPs were characterized for drug content and drug release rate using HPLC, particlesize, particle size distribution and ζ-potential using dynamic light scattering, surface morphology using scanning electron microscopy (SEM) and atomic force microscopy (AFM), and drug physical and chemical integrity using differential scanning calorimetry (DSC) and Fourier transform infrared (FTIR) spectroscopy. Spherical PLGA NPs with smooth and discrete surface were prepared. The physicochemical properties of the prepared NPs were investigated and the optimum formulation was selected. The selected formulation was monodispersed NPs 200.8±4.02nm in diameter and negatively charged surface (-21.03±3.08mV). PZQ- loaded PLGA NPs showed sustained release profile from the optimum formulation with the highest encapsulation efficiency and drug loading (94.19±3.46% and 47.09±3.46% respectively). Specific anti- schistosomal pAb specific against schistosome sAg was prepared, purified and characterized. Surface functionalization of the optimized PZQ-loaded PLGA NPs with antischistosomal pAb was then achieved using both physical adsorption and chemical conjugation methods using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and Nhydroxysuccinimide (NHS) mediated cross linking agents. The pAb- conjugated immuno-NPs showed higher coupling efficiency than the pAb- adsorbed NPs (89.31±1.78 and 64.2±2.87%, respectively). Re-evaluation of the physical properties of NPs and the reactivity of pAb after coupling reactions was performed. The immuno-NPs indicated optimum properties with preserved bioactivity of the attached antibodies. Thus, it was concluded that pAb-conjugated PLGA NPs provide an efficient and targeted delivery of PZQ, presenting a potential preliminary delivery system for treatment of Schistosomiasis in near future. |
| format | Thesis |
| id | oai:fount.aucegypt.edu:etds-2513 |
| institution | American University in Cairo (Egypt) |
| last_indexed | 2026-06-10T12:35:50.652Z |
| license_str | Other — see source repository |
| provenance_str_mv | Harvested via OAI-PMH from AUC Knowledge Fountain — bepress |
| publishDate | 2017 |
| publishDateRange | 2017 |
| publishDateSort | 2017 |
| publisher | AUC Knowledge Fountain |
| publisherStr | AUC Knowledge Fountain |
| record_format | dspace |
| source_str | AUC Knowledge Fountain — bepress |
| spelling | oai:fount.aucegypt.edu:etds-2513 Development of immuno- nanoparticles for targeting schistosoma parasites Abdul-Ghany, Eman Rabie Praziquantel (PZQ) is the drug of choice for treatment of schistosomiasis since its discovery in 1972. According to World Health Organization (WHO), schistosomiasis is the second most prevalent parasitic disease worldwide that has no effective vaccine yet. Schistosoma parasites infect more than 200 million people in about 76 countries and about 700 million people are at risk.PZQ is not only used for treatment of schistosomiasis, but it is also used for control of other parasitic diseases and it is included on the Model List of Essential Medicines of WHO. Parasitic diseases, despite their significant global burden, have been rather under researched by drug discovery companies as compared to other diseases mainly due to complexities of parasitic infections and lack of economic motivations. In such scenario, nanomedicine has a crucial role to play in improvement of the current anti-parasitic agents by their delivering in a targeted manner to the schistosome parasites in host blood circulation. Hence, selective drug delivery is an important approach with great potential for overcoming problems associated with the systemic toxicity and poor bioavailability of PZQ. This study aims at overcoming the inherent drawbacks of PZQ through formulation, optimization and evaluation of PZQ-loaded biodegradable PLGA “Poly (D,L lactide-coglycolide)” nanoparticles (NPs) that were surface conjugated with polyclonal antibodies (pAb) specific for schistosome surface antigens (sAg) for active targeting and treatment of schistosomiasis. PZQ was encapsulated in biodegradable PLGA NPs using single emulsion-solvent evaporation method. Various parameters were investigated and optimized like drug: polymer ratio, surfactant concentration and osmotic effect of adding salts to the external aqueous phase. PZQ-loaded NPs were characterized for drug content and drug release rate using HPLC, particlesize, particle size distribution and ζ-potential using dynamic light scattering, surface morphology using scanning electron microscopy (SEM) and atomic force microscopy (AFM), and drug physical and chemical integrity using differential scanning calorimetry (DSC) and Fourier transform infrared (FTIR) spectroscopy. Spherical PLGA NPs with smooth and discrete surface were prepared. The physicochemical properties of the prepared NPs were investigated and the optimum formulation was selected. The selected formulation was monodispersed NPs 200.8±4.02nm in diameter and negatively charged surface (-21.03±3.08mV). PZQ- loaded PLGA NPs showed sustained release profile from the optimum formulation with the highest encapsulation efficiency and drug loading (94.19±3.46% and 47.09±3.46% respectively). Specific anti- schistosomal pAb specific against schistosome sAg was prepared, purified and characterized. Surface functionalization of the optimized PZQ-loaded PLGA NPs with antischistosomal pAb was then achieved using both physical adsorption and chemical conjugation methods using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and Nhydroxysuccinimide (NHS) mediated cross linking agents. The pAb- conjugated immuno-NPs showed higher coupling efficiency than the pAb- adsorbed NPs (89.31±1.78 and 64.2±2.87%, respectively). Re-evaluation of the physical properties of NPs and the reactivity of pAb after coupling reactions was performed. The immuno-NPs indicated optimum properties with preserved bioactivity of the attached antibodies. Thus, it was concluded that pAb-conjugated PLGA NPs provide an efficient and targeted delivery of PZQ, presenting a potential preliminary delivery system for treatment of Schistosomiasis in near future. 2017-01-21T08:00:00Z thesis application/pdf https://fount.aucegypt.edu/etds/1505 https://fount.aucegypt.edu/context/etds/article/2513/viewcontent/M.Sc._20Thesis_20_Development_20of_20Immuno__20Nanoparticles_20for_20Targeting_20Schistosoma_20_28i_29_20Parasites_20__20Eman_20Abdul_Ghany_20__20800080271_20__20Septemberl_202016_20__20Updated.pdf The author retains all rights with regard to copyright. The author certifies that written permission from the owner(s) of third-party copyrighted matter included in the thesis, dissertation, paper, or record of study has been obtained. The author further certifies that IRB approval has been obtained for this thesis, or that IRB approval is not necessary for this thesis. Insofar as this thesis, dissertation, paper, or record of study is an educational record as defined in the Family Educational Rights and Privacy Act (FERPA) (20 USC 1232g), the author has granted consent to disclosure of it to anyone who requests a copy. Theses and Dissertations AUC Knowledge Fountain Praziquantel Schistosomiasis PLGA Nanoparticles Immuno-nanoparticles Adsorption EDC/ NHS urface Functionalization Schistosomicidal Physical Sciences and Mathematics |
| spellingShingle | Praziquantel Schistosomiasis PLGA Nanoparticles Immuno-nanoparticles Adsorption EDC/ NHS urface Functionalization Schistosomicidal Physical Sciences and Mathematics Abdul-Ghany, Eman Rabie Development of immuno- nanoparticles for targeting schistosoma parasites |
| title | Development of immuno- nanoparticles for targeting schistosoma parasites |
| title_full | Development of immuno- nanoparticles for targeting schistosoma parasites |
| title_fullStr | Development of immuno- nanoparticles for targeting schistosoma parasites |
| title_full_unstemmed | Development of immuno- nanoparticles for targeting schistosoma parasites |
| title_short | Development of immuno- nanoparticles for targeting schistosoma parasites |
| title_sort | development of immuno nanoparticles for targeting schistosoma parasites |
| topic | Praziquantel Schistosomiasis PLGA Nanoparticles Immuno-nanoparticles Adsorption EDC/ NHS urface Functionalization Schistosomicidal Physical Sciences and Mathematics |
| url | https://fount.aucegypt.edu/etds/1505 https://fount.aucegypt.edu/context/etds/article/2513/viewcontent/M.Sc._20Thesis_20_Development_20of_20Immuno__20Nanoparticles_20for_20Targeting_20Schistosoma_20_28i_29_20Parasites_20__20Eman_20Abdul_Ghany_20__20800080271_20__20Septemberl_202016_20__20Updated.pdf |
| work_keys_str_mv | AT abdulghanyemanrabie developmentofimmunonanoparticlesfortargetingschistosomaparasites |